Across Europe this week you’re seeing three main HealthTech threads: stepped‑up public funding (notably Ireland’s new ARC Hub), continued tightening of the MDR/IVDR–AI Act regime and selective early‑stage capital going into neuro and infrastructure‑style digital health. European MedTech this week is dominated by Brussels‑driven regulatory moves around MDR/IVDR and EUDAMED, plus UK steps to lean on CE‑marked devices, all against a backdrop of “industrial maturity” in funding a